Journal
TRANSLATIONAL ONCOLOGY
Volume 8, Issue 3, Pages 196-203Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.tranon.2015.03.011
Keywords
-
Categories
Funding
- New Drug State Key Project [009ZX09102-205]
- University of Cincinnati
- UCCOM Fund
- [R01CA158372]
Ask authors/readers for more resources
Pancreatic cancer remains one of the most intractable cancers, with a dismal prognosis reflected by a 5-year survival of similar to 6%. Since early disease symptoms are undefined and specific biomarkers are lacking, about 80% of patients present with advanced, inoperable tumors that represent a daunting challenge. Despite many clinical trials, no single chemotherapy agent has been reliably associated with objective response rates above 10% or median survival longer than 5 to 7 months. Although combination chemotherapy regimens have in recent years provided some improvement, overall survival (8-11 months) remains very poor. There is therefore a critical need for novel therapies that can improve outcomes for pancreatic cancer patients. Here, we present a summary of the current therapies used in the management of advanced pancreatic cancer and review novel therapeutic strategies that target tumor biomarkers. We also describe our recent research using phosphatidylserine-targeted saposin C-coupled dioleoylphosphatidylserine nanovesicles for imaging and therapy of pancreatic cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available